Deutsche Bank
PRLD icon

Deutsche Bank’s Prelude Therapeutics PRLD Stock Holding History

Deutsche Bank’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$148K Buy
+27,824
New +$121K ﹤0.01% 3374
2025
Q2 		– Sell
-80,723
Closed -$62.2K – 3704
2025
Q1 		$62.2K Sell
80,723
-43,176
-35% -$40.3K ﹤0.01% 3335
2024
Q4 		$159K Buy
123,899
+109,281
+748% +$145K ﹤0.01% 3162
2024
Q3 		$30.3K Hold
14,618
– – ﹤0.01% 3431
2024
Q2 		$55.7K Buy
+14,618
New +$59.5K ﹤0.01% 3302
2023
Q4 		– Sell
-446
Closed -$1.38K – 3684
2023
Q3 		$1.38K Buy
+446
New +$1.67K ﹤0.01% 3652
2022
Q2 		– Sell
-6,187
Closed -$43K – 4279
2022
Q1 		$43K Sell
6,187
-700
-10% -$6.4K ﹤0.01% 3883
2021
Q4 		$86K Buy
6,887
+350
+5% +$5.69K ﹤0.01% 3766
2021
Q3 		$205K Sell
6,537
-30,596
-82% -$991K ﹤0.01% 3556
2021
Q2 		$1.06M Buy
37,133
+547
+1% +$19.5K ﹤0.01% 2730
2021
Q1 		$1.58M Buy
36,586
+29,836
+442% +$1.98M ﹤0.01% 2350
2020
Q4 		$483K Buy
+6,750
New +$336K ﹤0.01% 2929

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Deutsche Bank's PRLD Position: Q2 2026 in Review

Deutsche Bank opened a new position in Prelude Therapeutics (PRLD) in Q2 2026: 27,824 shares worth $148K. The stake represents ﹤0.01% of the portfolio and ranks #3374 among its holdings. This is a return to the name: Deutsche Bank previously reported a position in PRLD as recently as Q1 2025.

Deutsche Bank first reported a position in PRLD in Q4 2020 and has held it in 12 quarters since. The position peaked at $1.58M in Q1 2021. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Deutsche Bank held 27,824 shares of Prelude Therapeutics worth $148K as of Q2 2026.
  • Prelude Therapeutics was a new Deutsche Bank position in Q2 2026.
  • Prelude Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #3374 holding.
  • Deutsche Bank first reported a position in Prelude Therapeutics in Q4 2020 and has held it in 12 quarters since.
  • Deutsche Bank's Prelude Therapeutics position peaked at $1.58M in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.